- Home
- VSTM
VSTM
Verastem Inc.
as 07-05-2024 12:39pm EST
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | NEEDHAM |
| Market Cap: | N/A | IPO Year: | 2012 |
| Target Price: | $25.69 | AVG Volume (30 days): | 769.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.41 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.80 - $14.22 | Next Earning Date: | 08-06-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 13647.06% |
Stock Insider Trading Activity of Verastem Inc. (VSTM)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Calkins Daniel | VSTM | Chief Financial Officer | Jun 18 '24 | Sell | $3.16 | 67 | $211.72 | 47,318 | SEC Form 4 |
| Paterson Dan | VSTM | President and CEO | Jun 17 '24 | Sell | $3.21 | 183 | $587.43 | 236,063 | SEC Form 4 |
| Paterson Dan | VSTM | President and CEO | Jun 17 '24 | Sell | $3.49 | 244 | $851.56 | 86,246 | SEC Form 4 |
| Gagnon Robert E. | VSTM | Director | Jun 17 '24 | Sell | $3.49 | 283 | $987.67 | 27,108 | SEC Form 4 |
| Gagnon Robert E. | VSTM | Director | Jun 17 '24 | Sell | $3.21 | 131 | $420.51 | 35,310 | SEC Form 4 |
| Stuglik Brian M | VSTM | Director | Jun 17 '24 | Sell | $3.49 | 593 | $2,069.57 | 89,047 | SEC Form 4 |
| Stuglik Brian M | VSTM | Director | Jun 17 '24 | Sell | $3.21 | 335 | $1,075.35 | 97,045 | SEC Form 4 |
| Calkins Daniel | VSTM | Chief Financial Officer | Apr 5 '24 | Sell | $10.87 | 6 | $65.22 | 8,535 | SEC Form 4 |
| Calkins Daniel | VSTM | Chief Financial Officer | Mar 25 '24 | Sell | $12.02 | 25 | $300.50 | 8,541 | SEC Form 4 |
| Calkins Daniel | VSTM | Chief Financial Officer | Mar 20 '24 | Sell | $11.07 | 55 | $608.85 | 8,566 | SEC Form 4 |
| Gagnon Robert E. | VSTM | Director | Mar 18 '24 | Sell | $10.71 | 283 | $3,030.93 | 27,521 | SEC Form 4 |
| Gagnon Robert E. | VSTM | Director | Mar 18 '24 | Sell | $10.38 | 130 | $1,349.40 | 27,391 | SEC Form 4 |
| Paterson Dan | VSTM | President and CEO | Mar 18 '24 | Sell | $10.71 | 244 | $2,613.24 | 86,672 | SEC Form 4 |
| Paterson Dan | VSTM | President and CEO | Mar 18 '24 | Sell | $10.38 | 182 | $1,889.16 | 86,490 | SEC Form 4 |
| Stuglik Brian M | VSTM | Director | Mar 18 '24 | Sell | $10.71 | 537 | $5,751.27 | 89,913 | SEC Form 4 |
| Stuglik Brian M | VSTM | Director | Mar 18 '24 | Sell | $10.38 | 273 | $2,833.74 | 89,640 | SEC Form 4 |
| Gagnon Robert E. | VSTM | Director | Feb 6 '24 | Sell | $13.70 | 9,204 | $126,094.80 | 27,804 | SEC Form 4 |
| Gagnon Robert E. | VSTM | Director | Jan 12 '24 | Sell | $10.95 | 9,204 | $100,783.80 | 37,008 | SEC Form 4 |
| Calkins Daniel | VSTM | Chief Financial Officer | Jan 5 '24 | Sell | $8.50 | 6 | $51.00 | 8,621 | SEC Form 4 |
| Calkins Daniel | VSTM | Chief Financial Officer | Dec 26 '23 | Sell | $8.08 | 25 | $202.00 | 8,350 | SEC Form 4 |
| Calkins Daniel | VSTM | Chief Financial Officer | Dec 20 '23 | Sell | $7.93 | 57 | $452.01 | 8,375 | SEC Form 4 |
| Paterson Dan | VSTM | President and CEO | Dec 18 '23 | Sell | $7.64 | 244 | $1,864.16 | 87,099 | SEC Form 4 |
| Paterson Dan | VSTM | President and CEO | Dec 18 '23 | Sell | $7.73 | 183 | $1,414.59 | 86,916 | SEC Form 4 |
Latest Verastem Inc. News
VSTM Breaking Stock News: Dive into VSTM Ticker-Specific Updates for Smart Investing
Business Wire
4 days ago
Verastem Oncology Announces Addition to Russell 3000® and Russell Microcap® Indexes
MT Newswires
a month ago
RBC Halves Price Target on Verastem to $16 From $32, Maintains Outperform Rating, Speculative Risk Qualifier
MT Newswires
a month ago
Top Midday Decliners
Zacks
a month ago
Verastem (VSTM) Up on Upbeat Early Pancreatic Cancer Study Data
Benzinga
a month ago
What's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday?
MT Newswires
a month ago
Sector Update: Health Care Stocks Advance Pre-Bell Friday
Pharmaceutical Technology
a month ago
ASCO 2024: Verastem’s combo therapy for pancreatic cancer hits early trial success
Clinical Trials Arena
a month ago
ASCO 2024: Verastem’s combo therapy for pancreatic cancer hits early trial success
Share on Social Networks:
Disclaimer
The information presented on this page, "VSTM Verastem Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.